{"id":"NCT01615198","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension","officialTitle":"A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2012-06-08","resultsPosted":"2015-08-18","lastUpdate":"2015-10-23"},"enrollment":588,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"Olmesartan","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"LCZ696","otherNames":[]}],"arms":[{"label":"LCZ696","type":"EXPERIMENTAL"},{"label":"Olmesartan","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.","primaryOutcome":{"measure":"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)","timeFrame":"Baseline, 10 weeks","effectByArm":[{"arm":"LCZ696","deltaMin":-22.71,"sd":0.91},{"arm":"Olmesartan","deltaMin":-16.11,"sd":0.92}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":79,"countries":["China","Hong Kong","Japan","Philippines","South Korea","Taiwan","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":296},"commonTop":["NASOPHARYNGITIS","HYPERURICAEMIA","UPPER RESPIRATORY TRACT INFECTION","DIZZINESS"]}}